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Abstract
Background:  A 4-week, uninterrupted treatment with 9-(2-phosphonyl-methoxypropyly)adenine
(PMPA, commonly called tenofovir) completely prevents simian immunodeficiency virus (SIVmne) infection
in cynomolgus macaques if treatment begins within 24 hours after SIVmne inoculation, but is less effective
if treatment is delayed or duration of treatment is shortened. Critical factors for efficacy include timing
and duration of treatment, potency of antiretroviral drug and a contribution from antiviral immune
responses. Therefore, we evaluated the impact of one or more treatment interruptions plus SIVmne re-
exposures on efficacy of PMPA treatment to prevent SIVmne infection in cynomolgus macaques. We also
evaluated whether macaques with pre-existing SIV immune responses show increased efficacy of
treatment. Eight PMPA-treated, virus-negative and seronegative macaques, and five PMPA-treated, virus-
negative but weakly or strongly seropositive macaques were re-inoculated with SIVmne and treated with
PMPA starting 24 hr post inoculation. Thereafter, they received either a 5-week treatment involving one
interruption plus one SIVmne challenge or a 10-week treatment involving six interruptions plus six SIVmne
challenges early during treatment. Parameters measured were plasma SIV RNA, SIV-antibody response,
CD4+ T lymphocyte subsets and in vivo CD8+ cell-suppression of virus infection.
Results: All seronegative macaques developed persistent antibody response beginning 4 to 8 weeks after
stopping PMPA-treatment in absence of viremia in a majority of macaques and coinciding with onset of
intermittent viremia in other macaques. In contrast, all weakly or strongly seropositive macaques showed
immediate increase in titers (> 1600) of SIV antibodies, even before the end of PMPA-treatment, and in
absence of detectable viremia. However, in vivo CD8+ -cell depletion revealed CD8 cell-suppression of
viremia and persistence of virus in the macaques as long as 2 years after PMPA-treatment, even in aviremic
macaques. Unlike untreated macaques, a treated macaque controlled viral replication and blocked CD4+
T cell depletion when challenged with a heterologus chimeric SIV/HIV-1 virus called SHIV89.6P.
Conclusion: A single interruption plus one SIVmne challenge was as sufficient as six interruptions plus six
SIVmne challenges in reducing efficacy of PMPA, but results in long-term persistence of virus infection
suppressed by CD8+ cells. Efficacy of PMPA treatment was highest in macaques with pre-existing SIV
immune responses.
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Background
Despite expanding use of antiretroviral therapy (HAART)
[1], which has clearly extended lives of persons infected
with human immunodeficiency virus (HIV) [2,3], the
virus continued to spread worldwide at nearly 5 million
new infections in 2005 [4]. Therefore, there is a need to
revisit proven strategies of HIV prevention with a goal to
understand their limitations and maximize their effective-
ness. A strategy of post exposure prophylaxis (PEP) using
highly potent antiretroviral drugs is effective in preventing
human immunodeficiency virus (HIV) transmission in
clinical situations where treatment can be started immedi-
ately after virus exposure. For example, in preventing ver-
tical transmission of HIV from HIV-infected mothers to
their infants [5,6], following occupational exposure to
HIV in blood and body fluids from HIV-infected persons
[7,8] or following sexual assault or intravenous drug use
[9,10]. Nevertheless, major barriers to the success of the
program are uncertainty as to the time of virus exposure
and poor compliance in completing treatment regimen,
partly due to drug toxicity [9-11]. Therefore, a regimen of
pre-exposure prophylaxis is being evaluated for prevent-
ing HIV infection in high-risk, HIV-negative persons, such
as sex workers whereby highly potent antiviral drugs are
taken before high-risk behavior [9,12]. The rationale for
pre or post exposure prophylaxis is that after HIV exposure
there is a brief window of time, before the virus spreads
systemically throughout the lymphoid organs, when initi-
ating potent antiretroviral therapy might prevent or mod-
ify viral replication. In clinical settings in which
compliance to treatment is poor and a potential exist for
re-exposures to virus, PEP should at least reduce virus to a
level sufficient to stimulate protective immune response
such as antiviral CD8+ cells and thus reduce the probabil-
ity of establishing persistent, productive infection. The
efficacy of such regimen depends on the timing and dura-
tion of treatment, use of highly potent antiretroviral drugs
and by immune responsiveness of the host [13,14].
We showed previously that early treatment with [(R)-9-(2-
phosphonylmethoxypropyl)adenine] (PMPA) can com-
pletely prevent SIVmne infection in cynomolgus macaques
if treatment begins within 24 hours post-inoculation
(p.i.) and is continued uninterrupted for 4 weeks, but is
less effective if the initiation of treatment is delayed or if
the duration of treatment was shortened [15,16]. The
highest efficacy achieved required an effective regimen
(i.e. 24-hour p.i., 28-day treatment) that maintained ther-
apeutic levels of PMPA to block the spread of virus, per-
haps with a contribution from antiviral immune
response. The less effective regimens such as delayed initi-
ation of PMPA treatment or shortened duration of PMPA-
treatment revealed the contribution of immune response
to efficacy. These regimens resulted in either delayed
establishment of virus infection or induced viral control
by macaques leading to transient infections [15]. Addi-
tionally, although the PMPA-protected macaques remain
free of detectable virus or SIV antibody response, they
show partial resistance to challenges with homologous or
heterologous SIV [17,18]. Even after the onset of SIV
infection in macaques, the initiation of PMPA treatment
during primary infection can induce immune suppression
of SIV infection [19-23] mediated by CD8+ lymphocytes
[18,24]. These studies indicated that regimens of early
PEP with PMPA induce antiviral immune responses in
macaques to control subsequent virus infection. The
CD8+ lymphocyte-mediated control of virus replication is
also a major mechanism by which early antiretroviral
treatment of acute HIV-1 infection induces immune con-
trol of viral replication in HIV-1 infected persons [25]. The
high potency of early PMPA treatment may be due to the
rapid intracellular phosphorylation of PMPA into its
active metabolites and the long half-life of these active
metabolites [26], which disrupts the replication cycle of
virus.
In the present study, we revisited our post exposure chem-
oprophylaxis against acute SIVmne infection in cynomol-
gus macaques [15-17] as an animal model for studying
factors involved in efficacy of early antiretroviral interven-
tion in HIV infection. We evaluated the impact of one or
more interruptions of PMPA-treatment plus re-exposures
to virus on the prevention of SIVmne infection and induc-
tion of CD8+ lymphocyte-mediated suppression of
viremia in cynomolgus macaques. We also evaluated
whether the efficacy of early PMPA treatment is greatest in
macaques with pre-existing immune response to SIV.
Results
Efficacy of PMPA-treatment
The study subjects, called PEP-macaques, were fourteen
cynomolgus macaques with a prior history of post expo-
sure prophylaxis (PEP) of SIVmne infection using tenofovir
(PMPA) or adefovir (PMEA) [15-17]. When grouped by
serologic outcome at the start of the present study (after 4–
5 years of follow-up study); the study subjects consisted of
eight virus-negative and SIV antibody-negative (V-Ab-)
PEP-macaques, four virus-negative but weak SIV-antibody
positive (V-Ab±) PEP-macaques, and two virus-negative
and strongly SIV antibody positive (V-Ab+) PEP-macaques.
To facilitate comparison of data for individual macaques
the history of individual macaques and their study groups
are shown in Table 1. The schedule and regimens of treat-
ment interruptions and SIVmne inoculations are shown
schematically in FIG 1.
Briefly, group A were three naïve, untreated cynomolgus
macaques were infection controls for SIVmne inoculum.
Group B were four V-Ab-PEP-macaques that were given a
10-week PMPA-treatment beginning 24 hours after intra-AIDS Research and Therapy 2006, 3:29 http://www.aidsrestherapy.com/content/3/1/29
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venous SIVmne inoculation, including treatment interrup-
tion and SIVmne challenge at weekly intervals during the
first six weeks of treatment. Group C were four V-Ab- PEP
macaques that were given a 5-week PMPA-treatment
beginning 24 hours after intravenous SIVmne inoculation,
including one treatment interruption plus SIVmne chal-
lenge at week 1 of treatment. Group D was one V-Ab+ -PEP
macaque that received a treatment regimen similar to
group B and three V-Ab± and one V-Ab+ -PEP macaques
that received a regimen similar to group C. Group E was
one untreated V-Ab± -PEP macaque used for SHIV89.6P
challenge to compare the level of viral control in treated
and untreated PEP-macaques. Virus infection in all
macaques was evaluated using levels of plasma SIV RNA,
A. A schematic drawing SIVmne inoculations and treatment regimens of different groups Figure 1
A. A schematic drawing SIVmne inoculations and treatment regimens of different groups. Arrows show schedule of SIVmne inoc-
ulation. The solid horizontal bar indicate schedule of daily PMPA treatment (30 mg/kg, subcutaneous). AID50 is 50% animal 
infectious dose of the SIVmne used in the studies. One AID50 of the SIVmne stock was approximately10 50% tissue culture infec-
tious dose (TCID50) by intravenous inoculation, and 100 TCID50 by intrarectal inoculation. Macaques in groups B (plus 
macaque 93043 in group D) received a 10-week PMPA treatment beginning 24 hours after virus inoculation, including treat-
ment interruption plus SIVmne re-inoculation with 10 AID50 SIVmne at weekly intervals during the first six weeks of treatment. 
Macaques in groups C and D received a 5-week PMPA treatment starting 24 hours after virus inoculation, including one treat-
ment interruption plus SIVmne re-inoculation with 10 AID50 SIVmne at week 1 of treatment. Macaque 95020 (group E) was 
untreated. B. The exact timing of events during the 72 hour interruption, including timing of SIVmne re-inoculation during the 
treatment interruption. Treatment was initiated 24 hours after SIVmne inoculation, then continued for 5 days. Thereafter, 
treatment was withheld for 72 hours, during which macaques were re-inoculated with SIVmne at 48 h and re-started on treat-
ment at 72 h. After the last inoculation, treatment was continued uninterrupted for 28 days. Note that the during the treat-
ment interruption, the 48-hour interval between the end of treatment and SIVmne re-inoculation was approximately one half-life 
of PMPA active metabolites in resting lymphocytes or three times the half-life in activated lymphocytes [26].
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SIV antibody responses and changes in lymphocyte sub-
sets.
All three naive, untreated macaques (group A) developed
persistently high levels of plasma viral RNA within week 1
after SIVmne inoculation and titers of SIV antibodies by
week 4, although the antibody response was lower in one
macaque (macaque 98034) than in the other two
untreated macaques (Fig. 2 and 3, group A).
When four V-Ab- PEP macaques (group B) received a 10-
week PMPA treatment starting 24 hours after SIVmne inoc-
ulation, including treatment interruptions plus SIVmne
challenges at weekly intervals during the first six weeks of
treatment, two macaques remained viremia-negative
while two developed intermittent levels of plasma viral
RNA beginning 2 – 8 weeks after stopping PMPA treat-
ment. However, all the four V-Ab- PEP macaques devel-
oped persistently high titers of SIV antibodies in plasma
beginning 4–8 weeks after stopping PMPA treatment (Fig.
2 and 3, group B)
Similarly, when four V-Ab-  PEP macaques (group C)
received a 5-week PMPA treatment starting 24 hours after
SIVmne inoculation, including treatment interruption plus
SIVmne challenge only at week 1 (i.e. after a 5-day treat-
ment) of treatment, three macaques remained viremia-
negative but one developed intermittent levels of plasma
viral RNA beginning 3 weeks after stopping PMPA treat-
ment. However, all the four V-Ab- PEP macaques devel-
oped persistently high titers of SIV antibodies by 4 weeks
after stopping PMPA treatment (Fig. 2 and 3, group C).
Table 1: Macaque history and regimen of post exposure prophylaxis.
Group Macaque Treatment regimens
Uninterrupted PEP1 Outcome after 4–5 years.2 Second PEP regimen3
A 98021 Naïve V-Ab- Untreated
98034 Naïve V-Ab- Untreated
98035 Naïve V-Ab- Untreated
B 93192 24 h pi 28 d V-Ab- (5) 10 wk, 6 ti
93208 24 h pi 28 d V-Ab- (5) 10 wk, 6 ti
95025 24 h pi 28 d V-Ab- (4) 10 wk, 6 ti
95044 24 h pi 28 d V-Ab- (4) 10 wk, 6 ti
C 93194 -48 h pi 28 d V-Ab-(5) 5 wk, 1 ti
95054 24 h pi 28 d V-Ab- (4) 5 wk, 1 ti
93217 24 h pi 28 d V-Ab- (5) 5 wk, 1 ti
93193 4 h pi 28 d V-Ab- (5) 5 wk, 1 ti
D M94312 24 h pi 28 d V-Ab± (4) 5 wk, 1 ti
M95033 72 h pi 28 d V-Ab± (4) 5 wk, 1 ti
95053 24 h pi 10 d V-Ab± (4) 5 wk, 1 ti
93040 -48 h pi, 28 d +SIV 
challenge
V-Ab+ (5) 5 wk, 1 ti
93043 -48 h pi, 28 d +SIV 
challenge
V-Ab+ (5) 10 wk, 6 ti
E 95020 24 h pi 10 d V-Ab± (4) NONE
All macaques in this study were cynomolgus macaques (Macaca fasicularis). 
1PEP, post-exposure chemoprophylaxis; uninterrupted PEP (1st PEP) was performed using SIVmne infection and PMPA or PMEA as described in 
studies already published [15-17] 4–5 years prior to the present study (2nd PEP). The uninterrupted PEP regimen such as 24 h pi 28 d indicates 24 
hours post inoculation and 28 days of treatment. 
2V-Ab- indicates virus-negative and antibody-negative; V-Ab± indicates virus-negative and weakly seropositive, V-Ab+ indicates virus-negative and 
strongly seropositive. The numbers in brackets refers to years after uninterrupted PEP for follow-up of each macaque. Macaques 93040 and 93043 
had been challenged with SIVsmmpBj14 at 12 months after uninterrupted PEP as described previously [17] prior to being used in the present study. 
3For second PEP regimen, all previously SIV-exposed and PMPA-treated macaques were divided into groups (B – E) based in the pre-existing SIV-
antibody response. Group A were three naïve macaques that served as infection controls for SIVmne virus stock. Macaques in group B and one 
macaque (93043) in group D were given a 10-week (10 wk) PMPA treatment that included weekly treatment interruption(ti) plus SIVmne challenge 
for the first six weeks of treatment (i.e. 10 wk, 6 ti). Macaques in groups C and D were given a 5-week (5 wk) PMPA treatment that included a 
single treatment interruption (ti) plus SIVmne challenge during the first week of treatment (i.e. 5 wk, 1 ti). Macaque 95020 in group E received 
uninterrupted PMPA PEP but not the second PMPA PEP and remained virus-negative and weakly seropositive throughout the follow-up studies.AIDS Research and Therapy 2006, 3:29 http://www.aidsrestherapy.com/content/3/1/29
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In contrast, when three V-Ab± PEP macaques and two V-Ab+
PEP macaques (group D) received a 10-week or 5-week
PMPA treatment regimen similar to that for group B or C,
all five macaques remained viremia-negative throughout
the 26-weeks of follow-up. Moreover, they all showed
immediate increase in titers of SIV antibodies plasma
within 2 weeks after the initial SIV inoculation, even
before PMPA treatment ended (Fig. 2 and 3, group D).
Analysis of lymphocyte subsets
To determine whether the PMPA treatment also protected
or improved the levels of CD4+ lymphocytes in peripheral
blood, the absolute numbers of CD4+ lymphocytes and
ratios of CD4:CD8 were analyzed for the different groups.
The three naïve, untreated macaques showed a gradual
decrease in CD4+ lymphocytes from 2379 ± 289/uL blood
(0.987 ± 0.297 CD4:CD8 ratio) before SIV inoculation to
Plasma viral load levels in untreated and PMPA-treated macaques after intravenous inoculation with uncloned SIVmne Figure 2
Plasma viral load levels in untreated and PMPA-treated macaques after intravenous inoculation with uncloned SIVmne. Group A 
were naïve untreated macaques. Macaques in group B (plus macaque 93043 in group D) received a 10-week PMPA treatment 
beginning 24 hours after virus inoculation, including treatment interruption plus SIVmne re-inoculation at weekly intervals during 
the first six weeks of treatment. Macaques in groups C and D received a 5-week PMPA treatment starting 24 hours after virus 
inoculation, including one treatment interruption plus SIVmne re-inoculation at week 1 of treatment. SIV RNA in plasma meas-
urements were performed at Bayer Diagnostics (Berkeley, CA) using a branched DNA (bDNA) signal amplification assay for 
SIV. This bDNA assay has a lower-limit of detection of125 RNA copies/ml.
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1240 ± 850/uL blood (0.835 ± 0.171 CD4:CD8 ratio) by
20 weeks of p.i.
The four V-Ab- PEP macaques (group B) that received
weekly treatment interruptions plus SIVmne  challenges
during the first six weeks of a 10-week PMPA treatment
showed no change in the CD4+ T cells from 1648 ± 527/
uL blood (CD4:CD8 ratio of 1.278 ± 0.349) before treat-
ment to 1608 ± 969/uL blood (CD4:CD8 ratio of 1.162 ±
0.298) by 20 weeks p.i. However, the four V-Ab- PEP
macaques (group C) that received treatment interruption
plus SIVmne challenge only at week 1 of a 5-week PMPA
treatment showed gradual increase in CD4+ lymphocytes
from 1589 ± 474/uL blood (CD4:CD8 ratio of 0.887 ±
0.270) before treatment to 2037 ± 408/uL blood
(CD4:CD8 ratio of 1.047 ± 0.528) by 20 weeks p.i. Simi-
larly, the five V-Ab± or V-Ab+PEP macaques (group D) that
received regimen similar to that for group B or C had grad-
ual increase in CD4+ lymphocytes from 1523 ± 503/uL
blood (CD4:CD8 ratio of 1.041 ± 0.371) before treatment
Anti-SIV IgG antibody response in untreated and PMPA-treated macaques after intravenous inoculation with uncloned SIVmne Figure 3
Anti-SIV IgG antibody response in untreated and PMPA-treated macaques after intravenous inoculation with uncloned SIVmne. 
Group A were naïve untreated macaques. Macaques in group B (plus macaque 93043 in group D) received a 10-week PMPA 
treatment beginning 24 hours after virus inoculation, including treatment interruption plus SIVmne re-inoculation at weekly 
intervals during the first six weeks of treatment. Macaques in groups C and D received a 5-week PMPA treatment starting 24 
hours after virus inoculation, including one treatment interruption plus SIVmne re-inoculation at week 1 of treatment. Titers 
are expressed as the reciprocal of the highest dilution that was positive by HIV-2 EIA (Sanofi-Pasteur, Redmond, WA). The 
lowest plasma dilution used was 1:40.
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to 1849 ± 753/uL blood (CD4:CD8 ratio of 1.087 ±
0.347) by 20 weeks p.i.
CD8+ lymphocyte-suppression of viremia
Control of viremia by CD8 T-cells has been found to be
one of the major mechanisms for antiretroviral-induced
host control of viral replication [18,24,25]. Therefore,
depletion of CD8+ lymphocytes at several years after
PMPA treatment T-cells would show both the induction
and persistence of immune control of infection in the PEP
macaques. Therefore, to demonstrate the presence and
persistence of CD8+ lymphocyte-suppression of virus in
PEP macaques, we performed in vivo CD8-cell depletion at
2 years after PMPA-treatment of four macaques (Fig.4).
Two macaques (93194, 93217) were from group C and
two (93040, 93043) were from group D. Of these four
macaques, only macaque 93217 had developed detecta-
ble levels of plasma viremia before CD8-depletion. All
other three macaques had no detectable plasma viremia
prior to CD8-depletion. We used monoclonal antibody
that depletes CD8+ T cells; including CD8+ natural killer
(NK) cells [27]. After the onset of CD8+-depletion all the
four macaques developed a rapid increase followed by
decrease in levels of plasma viral RNA (Fig.3). Plasma
viremia increased and then decreased to undetectable lev-
els inversely with the levels of CD8+ lymphocytes-cells in
peripheral blood. Moreover, the depletion of CD8+ lym-
phocyte-cells in vivo produced viremia in all macaques
including those macaques that had remained negative for
plasma viremia throughout the 2 years of follow-up.
Comparison of SHIV89.6P challenge in treated and 
untreated PEP macaques
Since all the study subjects had a history PMPA PEP, one
question was what the effect of pre-existing immunity
alone was without the second PMPA PEP regimen. To
investigate this question, we compared viral control after
a pathogenic, heterologus viral challenge with SHIV89.6P in
two PEP-macaques that were virus-negative and very
weakly SIV-antibody positive after the first PMPA PEP
[15], but one (M94312, group D) that received second
PEP regimen and one (macaque 95020, group E) that did
not. The SHIV89.6P – obtained originally from Dr. K.A. Rie-
mann () – is a chimeric virus of SIV/HIV-1 containing env
gene of HIV-189.6P on SIVmac239 backbone which causes
high viral loads and a rapid decline in CD4+ T-cell levels
in rhesus macaques [28] and cynomogus macaques [29].
After receiving second PMPA PEP, macaque M94312 fully
seroconverted and became persistently virus-negative
with high level of SIV antibodies, whereas Macaque
95020 remained persistently virus-negative and weakly
SIV antibody positive. Both macaques were challenged
intravenously with 10 AID50 SHIV89.6P virus (6.5 years
after first PMPA PEP or 2.5 years after second PMPA PEP).
Two naïve macaques (macaques 99111 and 99107)
served as infection controls for the SHIV89.6P inoculums.
The two-naïve macaques developed high levels of plasma
SIV RNA that reached maximum (7,705,800 – 22,340,000
copies/mL) by week 2 after SHIV89.6P inoculation and
remained persistent throughout the first 8 weeks of infec-
tion (Fig 5). Both macaques also developed a rapid
decrease in peripheral blood levels of CD4+ T cells from
an average of 914 ± 121 cells/μL (CD4:CD8 ratio of 0.715
+ 0.2) before inoculation to persistently low levels of 75 –
150 cells/μL (CD4:CD8 ratio of 0.01 – 0.09) blood during
primary infection (Fig 6). These macaques developed SIV
antibody response that was detectable by HIV-2 ELISA
beginning week 4 post inoculation (Fig 5).
Similarly, macaque 95020 developed high levels of
plasma SIV RNA that reached a maximum of 4,067,900
copies/mL week 1 post challenge and remained persistent
throughout primary infection (Fig 5). Plasma viremia was
accompanied by a rapid decrease in peripheral blood lev-
els of CD4+ T cells from 931 cells/μL (CD4:CD8 ratio of
1.016) before challenge to a persistent low levels of 220–
260 cells/μL (CD4:CD8 ratio of 0.15–0.2) by week 2 post
challenge (Fig 6). This macaque also became fully sero-
converted with high titers of SIV antibody response detect-
able by HIV-2 ELISA within 4 weeks post challenge. When
compared with the two naïve macaques, macaque 95020
had slightly low peak plasma viremia (4,067,900 versus
7,705,800 – 22,340,000 copies/mL) and less decline in
levels of CD4+ T cells (220–260 versus 75 – 150 CD4+ T
cells/uL).
In contrast, challenge of macaque M94312 with SHIV89.6P,
resulted in transient plasma viremia that reached maxi-
mum 206,577 copies/mL at week 1 post challenge and
was undetectable by week 4 post challenge (Fig 5). In
addition, macaque M94312 showed no depletion of
CD4+ T cells in peripheral blood; instead the CD4+ T cells
increased slightly from 773 cells/μL (CD4:CD8 ratio of
1.098) at pre-challenge to 1045–1108 cells/μL (CD4:CD8
ratio of 0.961 – 1.164) between weeks 4–8 after chal-
lenge(Fig 6). This macaque also showed a transient
increase in titers of SIV antibodies between weeks 2 – 6
post challenge. Thus, unlike macaque 95020 and the 2
naïve macaques, macaque M94312 controlled of
SHIV89.6P replication within 4 weeks after inoculation and
it completely blocked the depletion of CD4+ T cells from
peripheral blood.
Discussion
A 4-week, uninterrupted treatment using PMPA can com-
pletely block SIV from establishing infection in macaques
if treatment is started within 24 hours after intravenous
SIV inoculation, but is less effective if the initiation ofAIDS Research and Therapy 2006, 3:29 http://www.aidsrestherapy.com/content/3/1/29
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treatment is delayed or if the duration of treatment is
shortened [15,16]. In the present study, we show that
even when treatment begins 24 h p.i. a single interruption
and virus challenge was as sufficient as multiple interrup-
tions plus viral challenges in reducing the efficacy of
PMPA, instead results in persistent SIV antibody responses
and long-term CD8-cell mediated suppression of virus
infection. The highest efficacy showed by a 4-week, unin-
terrupted treatment regimen was most probably due to
maintenance of effective therapeutic level of PMPA neces-
sary to allow the infected cells initiated within 24 hours of
intravenous inoculation to decay completely without
spreading virus infection. However, the reduced efficacy
showed by interruption of treatment plus virus challenge
Relationship between levels of CD8+ cells in peripheral  blood and plasma viral load in macaques during in vivo deple- tion of CD8+ lymphocytes Figure 4
Relationship between levels of CD8+ cells in peripheral 
blood and plasma viral load in macaques during in vivo deple-
tion of CD8+ lymphocytes. Depletion of CD8+ lymphocytes 
was achieved by using the monoclonal anti-CD8 antibody 
(cMT807) as described in the text. Depletion studies were 
performed 2.3 years after the end of PMPA-treatment. Levels 
of CD8+ lymphocytes were measured by flow cytometry and 
plasma viral load was quantitated by a branched DNA 
(bDNA) signal amplification assay for SIV as described in the 
text. Macaque 93217 and 93194 were from group C. 
Macaque 93040 and 93043 were from group D.
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Plasma viral load (A) and SIV antibody response (B) in naïve  and PEP-macaques inoculated intravenously with 10 AID50  chimeric SIV/HIV-1 called SHIV89.6P Figure 5
Plasma viral load (A) and SIV antibody response (B) in naïve 
and PEP-macaques inoculated intravenously with 10 AID50 
chimeric SIV/HIV-1 called SHIV89.6P. PEP, post exposure 
prophylaxis. Macaques 95020 and M94312 were persistently 
virus-negative and weakly SIV-antibody positive (V-Ab±) after 
the first SIVmne infection/PMPA PEP regimen (1st PEP) [15]. 
Four years later, macaque M94312 received a second PEP 
regimen (2nd PEP) involving one treatment interruption plus 
SIVmne challenge at week 1 of a 5-week PMPA treatment. 
Thereafter, this macaque became persistently virus-negative 
and strongly-SIV antibody positive (V-Ab+). Macaque 95020 
was not given a second PEP and remained persistently virus-
negative and weakly-antibody positive (V-Ab±). Both 
macaques were then challenged with SHIV89.6P at the same 
time at 2.5 years after the 2nd PEP (i.e. 6.5 years after the 1st 
PEP). Two naïve macaques (99111 and 99107) served as 
infection controls. Plasma viremia was quantified by a 
branched DNA (bDNA) signal amplification assay for SIV by 
Bayer Diagnostics (Berkeley, CA). The target probes for the 
assay are designed to hybridize with the pol region of SIVmac 
strains of virus. This assay has a lower limit of detection 
of125 RNA copies/mL. Titers of SIV antibodies are 
expressed as the reciprocal of the highest dilution of plasma 
that was positive by HIV-2 EIA (Sanofi-Pasteur, Redmond, 
WA). The lowest plasma dilution used was 1:20.
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was most likely due to decreased PMPA levels, which
allowed transient infections to occur, thereby re-setting
decay of infected cells. As a result the level of SIV infection
in macaques was not sufficient to establish full infection
but was sufficient to induce persistent SIV antibody
responses and CD8 cell-mediated suppression of virus
infection. In the present study, the first interruption of
treatment occurred after a 5-day treatment from the time
of SIVmne inoculation and lasted 3 days during which
macaques were re-inoculated with SIVmne. It is possible
that, for the virus-negative and antibody negative
macaques (V-Ab-PEP macaques in groups B and C, if treat-
ment was interrupted later (e.g. on day 20 of treatment)
during the 28-day treatment or if the interruption lasted
less than three days (e.g. 1–2 days), the efficacy of PMPA
would have been preserved due to the long intracellular
half-life of the active metabolites of PMPA [26].
The findings that a majority of previously seronegative
macaques developed SIV antibodies 4–8 weeks after treat-
ment in the absence of detectable viremia or after tran-
sient viremia indicated that these macaques developed
control of SIV replication by the time treatment was with-
drawn, consistent with previous studies [19-23]. In addi-
tion, the findings that all the previously, weakly and
strongly seropositive macaques (V-Ab±  PEP macaques)
developed high titers of SIV antibodies within 2 weeks of
SIV inoculation, even before the end of treatment and in
complete absence of detectable viremia, indicated
immune memory response [30] to SIV in these macaques.
Therefore, these results indicate that the efficacy of post
exposure prophylaxis with PMPA can be significantly aug-
mented by the pre-existing immune responses to SIV. This
finding is consistent with that of other investigators that
showed that the efficacy of PMPA against acute or chronic
SIV infection in macaques is enhanced by the presence of
CD8+ T-cells [24]. PMPA itself can stimulate lymphocytes
or macrophages to secrete cytokines such as tumor necro-
sis factor (TNF) or chemokines such as RANTES [31,32],
which may have also contributed to the efficacy of PMPA.
Unlike PMPA, other antiretroviral agents such as AZT or
PMEA when given in post exposure regimen are incom-
pletely effective in blocking acute SIV infection in
macaques [33-35]. The high potency of PMPA may be
attributable to its rapid intracellular phosphorylation to
form active metabolites, the long intracellular half-life of
these active metabolites [26] and perhaps a capacity of
PMPA to activate immune cells such as monocytes or lym-
phocytes to secrete cytokines and chemokines [31,32].
Therefore, efficacy of post exposure prophylaxis for HIV
infection may depend critically not only on the timing of
initiation and duration of treatment, but also on the phar-
macological properties of specific antiretroviral agents
used. Good candidates include highly potent antiretrovi-
Lymphocyte subsets in naïve and PEP-macaques inoculated  intravenously with 10 AID50 chimeric SIV/HIV-1 called  SHIV89.6P Figure 6
Lymphocyte subsets in naïve and PEP-macaques inoculated 
intravenously with 10 AID50 chimeric SIV/HIV-1 called 
SHIV89.6P. Figure 1 shows absolute numbers of CD4 T cells. 
Figure 1B shows CD4:CD8 ratio. PEP, post exposure proph-
ylaxis. Macaques 95020 and M94312 were persistently virus-
negative and weakly SIV-antibody positive (V-Ab±) after the 
first SIVmne infection/PMPA PEP regimen (1st PEP) [15]. Four 
years later, macaque M94312 received a second PEP regimen 
(2nd PEP) involving one treatment interruption plus SIVmne 
challenge at week 1 of a 5-week PMPA treatment. Thereaf-
ter, this macaque became persistently virus-negative and 
strongly-SIV antibody positive (V-Ab+). Macaque 95020 was 
not given a second PEP and remained persistently virus-nega-
tive and weakly-antibody positive (V-Ab±). Both macaques 
were then challenged with SHIV89.6P at the same time at 2.5 
years after the 2nd PEP (i.e. 6.5 years after the 1st PEP). Two 
naïve macaques (99111 and 99107) served as infection con-
trols. Lymphocyte subsets are analyzed in peripheral blood 
by FACScan for absolute number of CD4+CD3+ T lym-
phocytes and CD8+CD3+ T lymphocytes and used to calcu-
late the ratio of CD4:CD8 T lymphocytes in peripheral 
blood.
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ral agents such as PMPA, which are easily activated in vivo,
have long intracellular half-life of active drug, could acti-
vate immune system and have good safety profile.
Induction of CD8 cell-suppression of viremia is one of the
mechanisms by which antiretroviral treatment, including
PMPA, induces host control of virus infection
[13,18,24,25]. We previously demonstrated that PEP
macaques exhibit considerable CD8+ lymphocyte sup-
pression of SIVmne in vitro even at CD8:CD4 ratios of 1:2
and mild suppression at ratios 1:10 [17]. Our studies
show that interrupted PMPA treatment resulted in CD8+
cell-suppression of viremia that persisted for more than 2
years, even in macaques that showed no evidence of
viremia. (Whether macaques previously had intermittent
viremia or no detectable viremia, the results were the
same: plasma viral RNA increased and then decreased to
undetectable levels inversely with the levels of CD8+ lym-
phocytes in peripheral blood). These results demonstrate
the persistence of CD8+T-cell suppression of virus infec-
tion. At the same time these results demonstrate the long-
term persistence of virus in the macaques, ready to repli-
cate immediately after removal of CD8+ T cells even in
macaques without any detectable virus. Such a persistence
of virus in macaque may itself be a stimulant maintaining
CD8 T-cell suppression of virus replication in the
macaques. These results are consistent with those of other
investigators showing persistence of vaccine virus as the
immune correlate of protection against late onset of AIDS
in macaques [36].
A previous study showed that when a 28-day PMPA PEP
regimen is used against SIVsmE660  infection in rhesus
macaques, it can induce CD8+ cell-mediated control of
viral replication and resistance to homologous challenge
or heterologous challenge with SIVmac39 [18]. However, a
similar regimen fails if SIVmac239 is used as the infecting
virus in PMPA PEP [37]. Thus, the results of PMPA PEP
using SIVmne  in cynomolgus macaques in the present
study may not apply necessarily to other SIV isolates or
other species of macaques, or to antiretroviral regimens
such as pre-exposure prophylaxis that completely block
virus infection without inducing CD8+ immune
responses. However, the results in the present study were
obtained using SIVmne infection in cynomolgus macaques
under specified conditions in which (i) PMPA treatment is
started 24 hours after SIVmne inoculation, (ii) the first
treatment interruption plus SIVmne challenge was started
after a 5-day treatment, (iii) each treatment interruption
lasted 3 days and macaques were challenged with SIVmne
on the second day of interruption, and (iv) treatment was
continued for at least 28 days after the last SIVmne chal-
lenge.
One question was how much the preexisting immunity
contributed to the viral control in the PEP-macaques in
the present study. This question was addressed by com-
paring the outcome of SHIV89.6P challenge in two PEP-
macaques (95020 and M94312) that had similar out-
comes from first PMPA PEP, but one macaque M94312
that received second PMPA PEP regimen whereas one
(macaque 95020) did not. After the initial PMPA PEP
both macaques had no detectable viremia, but they had
very weak SIV-specific antibody response. Four years later,
macaque M94312 was given second PEP regimen and
thereafter became persistently virus-negative but strongly
positive for SIV antibody response. When challenged
intravenously with 10 AID50 SHIV89.6P. macaque 95020
failed to control active viral replication and depletion of
CD4+ T cells throughout the course of primary infection.
In contrast, macaque M94312 completely controlled viral
replication within 4 weeks of inoculation and completely
blocked the depletion of CD4+ T cells. Although the
number of macaques in this challenge study was small,
the marked viral control by M94312 in contrast to
macaque 95020 was most probably a contribution of sec-
ond PMPA PEP regimen. It is conceivable that the individ-
ual PEP-macaques or macaque groups such as V-Ab-, V-
Ab± or V-Ab+ had different levels of pre-existing SIV spe-
cific CD8+ cell responses which contributed to the protec-
tion of macaques independent of PMPA. Van Rompay et
al [24] demonstrated that CD8+ T cells enhanced the effi-
cacy of PMPA treatment in controlling SIV infection.
Therefore, in the presence of PMPA treatment, preexisting
immune response might interact additively with PMPA to
control infection. The outcome would depend on the
level of pre-existing immunity [14]. Although our study
has a limitation in its capacity to establish the absolute
contribution in each macaque group, it provides an
insight into relative contribution to efficacy by comparing
the results of efficacy between macaque groups. For exam-
ple, our findings show that all the seronegative (V-Ab-)
PEP macaques in groups B and C seroconverted only
when PMPA treatment had stopped for at least 4 – 8
weeks, irrespective of 5-week or 10-week duration of treat-
ment. Similarly, the onset of transient or intermittent
viremia in the three macaques in those groups also devel-
oped 2 – 8 weeks after stopping PMPA treatment. In con-
trast the macaques in group D that received a similar
treatment regimen, but which were previously weakly
seroposotive, became fully seroconverted within two
weeks of SIV inoculation, even before the end of PMPA
treatment. These findings suggest strongly that, viral con-
trol was more dependent on PMPA treatment in the previ-
ously seronegative PEP macaques than in the previously
weakly or strongly seropositive PEP macaques.
Overall, our studies confirm that early initiation of potent
antiretroviral treatment and strict compliance to the dura-AIDS Research and Therapy 2006, 3:29 http://www.aidsrestherapy.com/content/3/1/29
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tion of treatment are critical factors for the success of post
exposure prophylaxis. The initiation of PMPA treatment
during chronic SIV infection fails to control the rebound
of viremia after treatment is withdrawn [38]. However,
the initiation of PMPA treatment between 2 days to 6
weeks after SIV inoculation (i.e. during the primary phase
of acute SIV infection) results in partial immune control
of SIV rebound [19-23]. Yet, for a preventive treatment
against HIV to be effective, the treatment must block the
HIV from ever establishing systemic infection in the lym-
phoid organs [39]. We have found that the most effective
regimen for blocking SIV infection in macaques is a 4-
week, uninterrupted treatment using PMPA beginning
before or within 24 hours of SIV intravenous inoculation
[15,16]. Our study shows that if the PMPA treatment is
interrupted and macaques are re-exposed to virus, then
the complete protection from SIV infection is abrogated.
Despite the lack of complete protection, a majority of
macaques still benefit by developing long-term immune
control of virus infection. More over the use of structured
treatment interruptions of highly active antiretroviral
therapy in HIV-infected persons [13,25] or in SIV-infected
macaques [22] has been shown to induce the immune
control virus infection. The effectiveness of such regimens
depends on early initiation of treatment, the potency of
the antiretroviral drug, and the immune responsiveness of
the host [14]. In addition, a recent clinical trial in human
found that under controlled conditions of CD4-guided
treatment, scheduled treatment interruptions may also be
beneficial in reducing the total amount of antiretroviral
drug used, and thus reduce cost as well as prevent drug
toxicity without the risk of developing drug resistance and
loss of efficacy of treatment [40]
Conclusion
In order for the regimen of post exposure prophylaxis to
be effective in preventing HIV transmission in persons
exposed to HIV in blood or body fluids from HIV-infected
persons, the exposed individuals need to comply with the
prescribed regimen of potent antiretroviral treatment
started as early as possible. However, in cases of noncom-
pliance to treatment regimen, our study shows that there
is still a benefit to completing treatment because inter-
rupted regimens can reduce the possibility of an estab-
lished persistent viral replication and instead modifies the
kinetics of viral replication to induce immune control of
the infection. Our study also implies that post-exposure
regimens of PMPA treatment in the SIV/macaque is a use-
ful animal model for inducing long-term immune control
of virus replication and thus useful for investigating the
nature of protective immune responses and strategies of
therapeutic vaccination or immune boosting against HIV.
Materials and methods
Macaques
The study subjects, henceforth called post-exposure
prophylaxis (PEP) macaques, were fourteen Cynomolgus
macaques (Macaca fascicularis) that had been previously
inoculated intravenously with SIVmne, then treated with
PMPA or PMEA [15-17] and evaluated for 4 to 5 years
(Table 1). Three naïve macaques served as controls for
infectivity of SIVmne  (group A). Eight of the PEP-
macaques, called V-Ab- PEP-macaques (groups B and C),
were completely protected from infection since they had
no detectable virus or SIV antibodies throughout the 4 – 5
years of follow-up. Four PEP-macaques (three are in
group D and one is in group E), called V-Ab±  PEP-
macaques, had transient infection early after treatment
and thereafter were free of virus but developed weak SIV
antibody response (ELISA titers less than 1:200, and 1–2
bands on SIV immunoblot). Two PEP-macaques, called V-
Ab+ PEP-macaques (in group D), had been completely
protected by treatment but when challenged with a highly
pathogenic, heterologous virus (SIVsmmPBj14), they resisted
the challenge and became persistently positive for SIV
antibodies [17]. Care and husbandry of all macaques were
in strict conformance with federal guidelines. All proce-
dures were approved by the Institutional Animal Care and
Use Committee at the University of Washington.
Virus inoculum
The SIVmne stock used in the second PMPA PEP regimens
was derived from the supernatant of uncloned SIVmne
propagated in HuT 78 cells and expanded in macaque
PBMCs [15,16]. One milliliter of the stock contained
10,000 viral particles of 50% tissue culture infectious
doses (TCID50) as determined in human T-cell lines or
1,000 50% animal infectious doses (AID50) as determined
by intravenous inoculation of macaques, or100 AID50 as
determined by intrarectal inoculation of macaques. The
SHIV89.6P stock used in the post PEP challenge was origi-
nally obtained from Dr. K. A. Reimann (Beth Israel Hos-
pital, Boston MA, Reimann et al 1996) and propagated in
phytohemagglutinin-A-stimulated PBMCs from naïve
pigtailed macaques [40]. One milliliter of the stock con-
tained 10,000 TCID50 as determined in MT-2 cells or
1,000 AID50 by intravenous inoculation in macaques.
Regimen of post-exposure prophylaxis
The PMPA PEP regimen used in this study is illustrated
schematically in Figure 1, to show the schedule of SIVmne
inoculations and treatment interruptions for different
groups. Three naïve macaques were used as untreated con-
trol (group A). Fourteen PEP macaques were divided into
groups based on the level of their pre-existing SIV anti-
body response. The eight V-Ab-  PEP-macaques were
divided into two groups (B and C) of four macaques each.
Three V-Ab± PEP-macaques and two V-Ab+ PEP-macaquesAIDS Research and Therapy 2006, 3:29 http://www.aidsrestherapy.com/content/3/1/29
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formed group D. One V-Ab±  PEP-macaque (95020)
formed group E. All the macaques in groups A – D were
first inoculated intravenously with 1AID50 (10 TCID50) of
SIVmne on day 0 and then reinocluated intravenously 7
days later with 10 AID50 (100 TCID50) SIVmne. All PEP-
macaques in groups B to D were started on PMPA treat-
ment (30 mg/kg per day, subcutaneously) beginning 24
hours after initial intravenous SIV inoculation. After 5
days of daily dosing, treatment was interrupted for 72
hours while macaques were re-inoculated intravenously
with 10 AID50 SIVmne. Then daily dosing resumed 24
hours after re-inoculation for additional 28 days. How-
ever, all macaques in group B and one macaque (93043)
in group D received additional interruptions of PMPA-
treatment plus re-challenge with SIVmne for six weeks. For
these macaques, treatment was interrupted for 72 hours
while macaques were re-inoculated intrarectally with 10
AID50 (1, 000 TCID50) SIVmne at weekly intervals until
week 6 after initial SIVmne inoculation. Thereafter, they all
resumed daily dosing for additional 28 days.
Depletion of CD8+ T cells in vivo
cM-T807 anti-CD8 monoclonal antibody was received
from Maine Biotechnology Services (Portland, ME 04103)
and Covance Research Products Inc. (Denver, PA 17517).
At 120 weeks from the beginning of the study, we per-
formed in vivo depletion of CD8 cells in four macaques
(93194, 93040, 93043 and 93217) using monoclonal
antibody (anti-CD8 cM-T807) as described by Schmitz et
al 1999 [27].
SHIV89.6P challenge
To investigate the relative contribution of the second PEP
regimen to viral control, we performed SHIV89.6P chal-
lenge on two PEP-macaques (95020 and M94312) that
had similar outcomes of being persistently V-Ab±after the
first PMPA PEP, but one (M94312) received second PMPA
PEP regimen while the other (95020) did not. As
described previously [15] macaque M94312 had previ-
ously been given PMPA treatment for 28 days beginning
24 hours after intravenous SIVmne inoculation. Macaque
95020 was given PMPA treatment for only 10 days begin-
ning 24 hours after SIVmne inoculation. Both macaques
had no detectable viremia (plasma SIV RNA or infectious
cells in peripheral blood), but they developed weak SIV-
antibody response beginning 24 weeks post inoculation
detectable as a very weak band for SIVgp120 on immuno-
blotting (Table 1). Four years later macaque M94312 was
given second PMPA PEP regimen of a 5-week PMPA treat-
ment involving a single treatment interruption plus
SIVmne challenge at week 1 of treatment. Thereafter, this
macaque became virus-negative but strongly SIV-antibody
positive (V-Ab+) (Fig 1, 2, 3). Macaque 95020 was not
given second PMPA PEP and remained persistently V-Ab±
(virus-negative and weakly-seroposoitive). In the present
study, we challenged both macaques intravenously
with10 AID50 SHIV89.6P (6.5 years after first PMPA PEP or
2.5 years after second PMPA PEP). Two naïve macaques
(macaques 99111 and 99107) served as infection controls
for the virus inoculum. Infection was evaluated during the
first 8 weeks after inoculation. The SHIV89.6P  – was
obtained originally from Dr. K.A. Riemann and expanded
in macaque PBMC. Its is a chimeric virus of SIV/HIV-1
containing env  gene of HIV-189.6P on SIVmac239 back-
bone which causes high viral loads and a rapid decline in
CD4+ T-cell levels in rhesus macaques [28] and cynomo-
gus macaques [29]. Plasma SHIV RNA was determined by
branched DNA (bDNA) signal amplification assay for SIV,
lymphocyte subsets by FACScan flow cytometry (Becton
Dickinson, San Jose, CA) for specific CD4+, CD8+, CD3+
and CD20+ lymphocyte subsets. SHIV-antibody response
was quantified by limiting dilution assay using a commer-
cial HIV-2 EIA (enzyme immunoassay) kit (Sanofi-Pas-
teur, Redmond, WA) as described previously [29,41].
Clinical observations
All macaques were observed daily for general physical
condition including appetite, stool consistency, and
demeanor. At predetermined time points during the 144
weeks of study, the animals were anesthetized with keta-
mine for thorough physical examination including body
weight and temperature. Blood was drawn for complete
blood count, serum chemistry, viriology, and lymphocyte
subset analyses. Data from clinical assessments was used
to monitor the course of SIV infection and clinical disease
including drug toxicity.
Laboratory assays
Laboratory determinations included plasma viral RNA,
titers SIV-antibodies and CD4+ and CD8+ T cell counts.
Quantitative assays for viral RNA in plasma were per-
formed at Bayer Diagnostics (Berkeley, CA) using a
branched DNA (bDNA) signal amplification assay for SIV.
This bDNA assay has a lower-limit of detection of125
RNA copies/ml [39]. Titers of SIV antibodies were deter-
mined by end-point dilution of plasma using HIV-2 EIA
kit (Sanofi-Pasteur, Redmond, WA). Lymphocyte subsets
in EDTA-blood were determined by FACscan using mouse
anti-human monoclonal antibodies that react with
macaque lymphocytes to determine the absolute numbers
of CD4+ and CD8+ T cells and the CD4:CD8 cell ratio was
calculated [41].
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